Rapastinel: Research & Studies

Research Overview#

Rapastinel (GLYX-13) has a moderate evidence base consisting of positive phase 2 clinical data, extensive preclinical mechanistic studies, and three failed phase 3 trials. The compound remains scientifically significant as a proof-of-concept for NMDA receptor modulation in depression.

Phase 2 Clinical Evidence#

Preskorn et al. (2015) -- Proof of Concept#

The phase 2 trial (PMID: 25782764) enrolled 116 subjects with treatment-resistant MDD. A single IV dose of GLYX-13 at 5 or 10 mg/kg significantly reduced HDRS-17 scores within 2 hours, with effects lasting approximately 7 days. An inverted U-shaped dose-response was observed. No psychotomimetic, dissociative, or sedative effects were reported.

Phase 3 Failure#

In March 2019, Allergan announced all three phase 3 studies failed to differentiate from placebo. Potential factors include high placebo response rates, dose selection challenges, and the practical limitations of weekly IV infusions in outpatient settings.

Preclinical Mechanism Studies#

Extensive preclinical work characterizes rapastinel's mechanism:

• Enhances LTP at Schaffer collateral-CA1 synapses
• Induces metaplasticity in medial prefrontal cortex
• Increases BDNF expression and TrkB phosphorylation
• Promotes AMPA receptor surface expression
• Stimulates hippocampal neurogenesis

Evidence Quality Assessment#

Research Evidence Context#

Rapastinel belongs to the Neuropeptide category of research peptides. The research evidence for Rapastinel spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Rapastinel:

Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent#

Authors: Preskorn S, Macaluso M, Mehra DO, et al. (2015) — Journal of Psychiatric Practice

Phase 2 proof-of-concept trial demonstrating that a single IV dose of GLYX-13 (5 or 10 mg/kg) produced rapid-onset antidepressant effects within 2 hours, lasting up to 7 days, without psychotomimetic side effects.

Key Findings:

• GLYX-13 at 5 and 10 mg/kg reduced HDRS-17 scores at days 1-7 vs placebo
• Onset of antidepressant effect within 2 hours of single IV dose
• Inverted U-shaped dose-response curve (1 and 30 mg/kg not significant)
• No psychotomimetic, dissociative, or sedative side effects observed

Limitations: Small sample size (n=116); single-dose design; no active comparator; high placebo response rate in some analyses

The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant#

Authors: Moskal JR, Burgdorf J, Stanton PK, et al. (2017) — Current Neuropharmacology

Review of rapastinel's development history, mechanism of action, and preclinical and clinical evidence supporting its potential as a rapid-acting antidepressant.

Key Findings:

• NMDA receptor glycine site partial agonism enhances synaptic plasticity
• Antidepressant effects converge with ketamine pathway without side effects
• Promotes LTP and metaplasticity in prefrontal cortex and hippocampus
• Effects mediated through AMPA receptor upregulation and BDNF release

Limitations: Review article; does not contain new clinical data; written before phase 3 failure

Evidence Quality Assessment#

The overall evidence level for Rapastinel is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Rapastinel have been identified:

• Understanding why phase 2 efficacy signals did not translate to phase 3 success
• Optimal dosing regimen for sustained antidepressant effects
• Development of orally bioavailable NMDA receptor modulators based on rapastinel pharmacology
• Potential applications beyond depression (PTSD, anxiety, cognitive enhancement)

Addressing these research gaps will be important for establishing a more complete understanding of Rapastinel's therapeutic potential and safety profile.

Related Reading#

• Rapastinel overview and research guide
• Rapastinel dosing protocols
• Rapastinel molecular structure